{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T12:02:41Z","timestamp":1704283361458},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T00:00:00Z","timestamp":1364428800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0060297","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T17:10:50Z","timestamp":1364490650000},"page":"e60297","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels"],"prefix":"10.1371","volume":"8","author":[{"given":"Shinya","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoko","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Fukamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3727\/096504008786991602","article-title":"Gene therapy for malignant pleural mesothelioma: Present and Future","volume":"17","author":"Y Tada","year":"2008","journal-title":"Oncol Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"BWS Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","article-title":"Losses of both products of the <italic>Cdkn2a\/Arf<\/italic> locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis","volume":"6","author":"DA Altomare","year":"2011","journal-title":"PLoS ONE"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2","article-title":"The gene for the cyclin-dependent-kinase-4 inhibitor, <italic>CDKN2A<\/italic>, is preferentially deleted in malignant mesothelioma","volume":"75","author":"JB Prins","year":"1998","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1073\/pnas.0808816106","article-title":"Activated TNF-\u03b1\/NF-\u03baB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesothelioma from <italic>Arf<\/italic> knockout mice","volume":"106","author":"DA Altomare","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"BWS Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2174\/092986707781389600","article-title":"Zoledronic acid -a multiplicity of anti-cancer action","volume":"14","author":"T Yuasa","year":"2007","journal-title":"Curr Med Chem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"JR Green","year":"2003","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"JR Green","year":"2004","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"A Skerjanec","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","article-title":"Bisphosphonates&apos; antitumor activity: an unravelled side of a multifaceted drug class","volume":"48","author":"P Cl\u00e9zardin","year":"2011","journal-title":"Bone"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1349-7006.2006.00163.x","article-title":"Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor","volume":"97","author":"E Nakataki","year":"2006","journal-title":"Cancer Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/92.8.636","article-title":"Adenovirus-mediated p14<sup>ARF<\/sup> gene transfer in human mesothelioma cells","volume":"92","author":"CT Yang","year":"2000","journal-title":"Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cell.2006.10.003","article-title":"The regulation of <italic>INK4\/ARF<\/italic> in cancer and aging","volume":"127","author":"WY Kim","year":"2006","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1593\/neo.06148","article-title":"p53-induced apoptosis occurs in the absence of p14<sup>ARF<\/sup> in malignant pleural mesothelioma","volume":"8","author":"S Hoskins-Donaldson","year":"2006","journal-title":"Neoplasia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1349-7006.2004.tb03202.x","article-title":"p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid","volume":"95","author":"J Kuroda","year":"2004","journal-title":"Cancer Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/mol.106.028837","article-title":"Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status","volume":"71","author":"B Ory","year":"2007","journal-title":"Mol Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"ZH Siddik","year":"2003","journal-title":"Oncogene"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2006.10.004","article-title":"Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells","volume":"250","author":"MS Benassi","year":"2007","journal-title":"Cancer Lett"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/cgt.2011.86","article-title":"Upregulated p53 expression activates apoptotic pathways in wild-type <italic>p53<\/italic>-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed","volume":"19","author":"Q Li","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1158\/1535-7163.MCT-07-0125","article-title":"<italic>p53<\/italic> therapy in a patient with Li-Fraumeni syndrome","volume":"6","author":"N Senzer","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"A Rossi","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"H Horie","year":"2007","journal-title":"Brit J Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood-2003-01-0305","article-title":"The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph<sup>+<\/sup> leukemia activity of imatinib mesylate","volume":"102","author":"J Kuroda","year":"2003","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"PD Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"S Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"key":"ref28","first-page":"1108","article-title":"Clinical effect of p53 gene Gendicine in treatment","volume":"13","author":"DH Liu","year":"2006","journal-title":"Chin J Cancer Prev Treat"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.cgt.7700148","article-title":"Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells","volume":"7","author":"Y Horio","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.cgt.7700319","article-title":"Cisplatin chemotherapy plus adenoviral <italic>p53<\/italic> gene therapy in EBV-positive and -negative nasopharyngeal carcinoma","volume":"8","author":"L Weinrib","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0092-8674(00)00115-X","article-title":"Ras and Rho GTPases: a family reunion","volume":"103","author":"D Bar-Sagi","year":"2000","journal-title":"Cell"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0060297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:28:25Z","timestamp":1539995305000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0060297"}},"subtitle":[],"editor":[{"given":"Dominique","family":"Heymann","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,28]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0060297","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,28]]}}}